Clinical Trial Update: A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1b/2a open-label study evaluating tivozanib in combination with paclitaxel in advanced or metastatic breast cancer. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Tivozanib (tivozanib)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED